You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Cobenfy
since
auto-detected in 3 stories
8 months ago
The company's future hinges on the success of Cobenfy, the company's new schizophrenia drug.
9 months ago
We're trimming our position in this drugmaker that is up more than 4% Thursday ○
The main story here remains Cobenfy, the company's new schizophrenia drug.
16 months ago
JPMorgan says own this drug stock. It's one Jim Cramer is itching to buy again ○
The Club remains optimistic about Bristol Myers and shares JPMorgan's enthusiasm about Cobenfy.
page 1 of 1